Skip to main content

Hypoattenuation Thickening on CT Prognostic After Left Atrial Appendage Occlusion

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Sept. 13, 2023 -- For patients with atrial fibrillation undergoing left atrial appendage occlusion (LAAO), high-grade hypoattenuation thickening (HAT) at follow-up computed tomography (CT) is associated with higher stroke risk, according to a study published online Sept. 5 in Radiology.

Xavier Iriart, M.D., from Bordeaux University Foundation in France, and colleagues conducted a prospective study to examine the association of HAT grade at follow-up CT after LAAO with clinical characteristics and outcomes. Patients with atrial fibrillation who had a high risk for stroke and underwent LAAO at two French medical centers from January 2012 to November 2020 were included. Overall, 412 patients who underwent follow-up CT at a mean of 4.2 ± 1.7 months after LAAO were analyzed.

The researchers found that low- and high-grade HAT were depicted in 23.8 and 5.1 percent of participants, respectively. Higher odds of antithrombotic drug discontinuation during follow-up were seen in association with high-grade HAT (odds ratio, 9.5), while low-grade HAT was associated with reduced odds of persisting left atrial appendage patency (odds ratio, 0.46). Stroke occurred in 5.8 percent of participants during a median follow-up of 17 months; high-grade HAT was associated with stroke (hazard ratio, 4.6), but no association was seen for low-grade HAT.

"These findings support the introduction of unequivocal standardized CT criteria for HAT grading, with important implications for treatment regimen optimization after implantation," the authors write.

Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023

WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.